Last week saw the publication of the European Medicines Agency report detailing what lessons can be learnt from the cases of unexpected N-nitrosamine impurities in sartans, which came to light mid-2018.

The 98-page report (found in full here: ) aims to prevent future cases by clarifying the roles and responsibilities of both the regulators and companies involved in the manufacture of medicines.

By amending guidance on the control of impurities, the EMA are taking a proactive approach to reduce the risk of similar situations occurring with other medicines, and should ensure that regulators are better prepared to manage cases of unexpected impurities in the future.

The recommendations, which now apply to ALL medicines, include developing additional guidance on a number of items such as sampling and testing, as well as improving communication with patients and healthcare professionals, further developing IT systems and expanding cooperation with international partners.

There has never been a more critical time to choose a pharma partner who is both well versed in the latest requirements and recommendations, and who is highly experienced in Nitrosamine testing.

Additional News

  • 19 December 2023

    Happy new year 2024

    As we bid farewell to 2023, it's time to express our deepest gratitude for the collaboration.

  • 4 December 2023

    Our new clinical unit in Ostrava comes to life

    It's a great pleasure to announce that after two years of hard work, the brand-new clinical unit in Ostrava with 36-beds capacity has been opened.

  • 3 October 2023

    Meet us at the heart of Pharma, CPHI 2023

    Quinta-Analytica is attending CPHI 2023 in Barcelona